HER2阳性-话题@MedSci

#HER2阳性#

183篇内容 | 4690人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1308569, encodeId=f6a51308569cb, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, objectType=article, longId=192476, objectId=9a771924e693, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a771924e693, replyNumber=0, likeNumber=38, createdTime=2020-04-20, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a771924e693, moduleTitle=FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a771924e693)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308568, encodeId=1d55130856809, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性乳腺癌又一ADC药物Enhertu，在中国申请临床试验, objectType=article, longId=192396, objectId=3bae1923961d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bae1923961d, replyNumber=0, likeNumber=72, createdTime=2020-04-18, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bae1923961d, moduleTitle=HER2阳性乳腺癌又一ADC药物Enhertu，在中国申请临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bae1923961d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308567, encodeId=7c2a130856ecd, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=王建东教授专访：ADC药物发力HER2阳性乳腺癌, objectType=article, longId=191104, objectId=f8a719110454, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8a719110454, replyNumber=0, likeNumber=71, createdTime=2020-04-01, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8a719110454, moduleTitle=王建东教授专访：ADC药物发力HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8a719110454)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308566, encodeId=a8451308566a9, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, objectType=article, longId=190853, objectId=1643190853f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1643190853f0, replyNumber=0, likeNumber=110, createdTime=2020-03-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1643190853f0, moduleTitle=抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1643190853f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308565, encodeId=f84813085657e, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=王涛教授专访：HER2阳性乳腺癌新近进展及ADC药物用药经验分享, objectType=article, longId=190497, objectId=b22519049e49, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b22519049e49, replyNumber=0, likeNumber=75, createdTime=2020-03-22, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b22519049e49, moduleTitle=王涛教授专访：HER2阳性乳腺癌新近进展及ADC药物用药经验分享, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b22519049e49)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308564, encodeId=8bb8130856434, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, objectType=article, longId=187241, objectId=618618e241e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=618618e241e2, replyNumber=0, likeNumber=54, createdTime=2020-02-04, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=618618e241e2, moduleTitle=欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=618618e241e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308563, encodeId=32031308563d6, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, objectType=article, longId=186821, objectId=44e318682186, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e318682186, replyNumber=0, likeNumber=54, createdTime=2020-01-29, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e318682186, moduleTitle=抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44e318682186)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308562, encodeId=ee021308562cc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=罗氏的ADC药物Kadcyla，在欧洲获批治疗HER2阳性早期乳腺癌, objectType=article, longId=185037, objectId=069518503ec3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=069518503ec3, replyNumber=0, likeNumber=71, createdTime=2019-12-23, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=069518503ec3, moduleTitle=罗氏的ADC药物Kadcyla，在欧洲获批治疗HER2阳性早期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=069518503ec3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308561, encodeId=89951308561f2, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, objectType=article, longId=184671, objectId=d1461846e154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1461846e154, replyNumber=0, likeNumber=60, createdTime=2019-12-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1461846e154, moduleTitle=NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1461846e154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308560, encodeId=5d421308560aa, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , objectType=article, longId=184672, objectId=90f01846e265, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90f01846e265, replyNumber=0, likeNumber=71, createdTime=2019-12-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90f01846e265, moduleTitle=阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90f01846e265)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308559, encodeId=3046130855987, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, objectType=article, longId=184670, objectId=4c281846e069, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c281846e069, replyNumber=0, likeNumber=0, createdTime=2019-12-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c281846e069, moduleTitle=NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c281846e069)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308558, encodeId=ac131308558d5, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批，开启HER2阳性晚期乳腺癌治疗新格局, objectType=article, longId=184654, objectId=946f18465458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=946f18465458, replyNumber=0, likeNumber=84, createdTime=2019-12-14, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=946f18465458, moduleTitle=罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批，开启HER2阳性晚期乳腺癌治疗新格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=946f18465458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308557, encodeId=f3a5130855e03, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=征服HER2阳性早期乳腺癌的临床挑战, objectType=article, longId=184055, objectId=b37c1840551f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b37c1840551f, replyNumber=0, likeNumber=99, createdTime=2019-12-04, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b37c1840551f, moduleTitle=征服HER2阳性早期乳腺癌的临床挑战, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b37c1840551f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308556, encodeId=f10413085560e, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性早期乳腺癌更佳辅助治疗方案, objectType=article, longId=182445, objectId=62c418244587, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62c418244587, replyNumber=0, likeNumber=89, createdTime=2019-11-07, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62c418244587, moduleTitle=HER2阳性早期乳腺癌更佳辅助治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62c418244587)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308555, encodeId=4b3c1308555e6, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=滕月娥教授：HER2阳性晚期乳腺癌治疗进展, objectType=article, longId=181940, objectId=d71d18194001, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d71d18194001, replyNumber=0, likeNumber=74, createdTime=2019-10-27, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d71d18194001, moduleTitle=滕月娥教授：HER2阳性晚期乳腺癌治疗进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d71d18194001)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308554, encodeId=27c213085546d, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=病例:曲妥“方舟”，HER2阳性乳腺癌的“新”希望, objectType=article, longId=181406, objectId=3d1d181406a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d1d181406a1, replyNumber=0, likeNumber=73, createdTime=2019-10-18, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d1d181406a1, moduleTitle=病例:曲妥“方舟”，HER2阳性乳腺癌的“新”希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d1d181406a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308553, encodeId=b96b1308553dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=2019ESMO|细说HER2阳性晚期乳腺癌治疗那些事儿, objectType=article, longId=181202, objectId=825818120299, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=825818120299, replyNumber=0, likeNumber=69, createdTime=2019-10-16, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=825818120299, moduleTitle=2019ESMO|细说HER2阳性晚期乳腺癌治疗那些事儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=825818120299)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308552, encodeId=c799130855268, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=专家共议MDT背景下HER2阳性胃癌的诊疗实践与思考, objectType=article, longId=181106, objectId=40d718110605, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40d718110605, replyNumber=0, likeNumber=59, createdTime=2019-10-15, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40d718110605, moduleTitle=专家共议MDT背景下HER2阳性胃癌的诊疗实践与思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40d718110605)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308551, encodeId=373e1308551d5, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=HER2阳性乳腺癌治愈不再遥远, objectType=article, longId=181070, objectId=0e491810e036, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e491810e036, replyNumber=0, likeNumber=92, createdTime=2019-10-15, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e491810e036, moduleTitle=HER2阳性乳腺癌治愈不再遥远, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e491810e036)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1308550, encodeId=2df2130855059, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, objectTitle=2019 ESMO|未雨绸缪——HER2阳性乳腺癌，别等疾病复发转移, objectType=article, longId=180697, objectId=623d18069eb4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623d18069eb4, replyNumber=0, likeNumber=62, createdTime=2019-10-10, rootId=0, userName=闆锋旦, userId=8409354, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623d18069eb4, moduleTitle=2019 ESMO|未雨绸缪——HER2阳性乳腺癌，别等疾病复发转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623d18069eb4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阳性

2020-05-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

FDA批准Seattle Genetics的口服酪氨酸激酶抑制剂Tukysa，治疗HER2阳性转移性乳腺癌

2020-04-20

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性乳腺癌又一ADC药物Enhertu，在中国申请临床试验

2020-04-18

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

王建东教授专访：ADC药物发力HER2阳性乳腺癌

2020-04-01

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

抗体药物偶联物ENHERTU获批治疗HER2阳性不可切除的或转移性乳腺癌

2020-03-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

王涛教授专访：HER2阳性乳腺癌新近进展及ADC药物用药经验分享

2020-03-22

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

欧洲药品管理局批准了Seattle Genetics公司的tucatinib用于局部晚期或转移性HER2阳性乳腺癌患者的市场授权申请

2020-02-04

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

抗体药物偶联物Enhertu达到HER2阳性转移性胃癌注册研究的主要终点

2020-01-29

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

罗氏的ADC药物Kadcyla，在欧洲获批治疗HER2阳性早期乳腺癌

2019-12-23

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

NEJM：曲妥珠单抗Deruxtecan用于HER2阳性转移性乳腺癌的二线治疗

2019-12-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

阿斯利康携手第一三共开发的trastuzumab deruxtecan研究结果喜人，HER2阳性转移性乳腺癌患者中位无进展生存期达16.4个月 

2019-12-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

NEJM：Tucatinib、曲妥珠单抗联合卡培他滨治疗转移性HER2阳性乳腺癌

2019-12-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批，开启HER2阳性晚期乳腺癌治疗新格局

2019-12-14

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

征服HER2阳性早期乳腺癌的临床挑战

2019-12-04

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性早期乳腺癌更佳辅助治疗方案

2019-11-07

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

滕月娥教授：HER2阳性晚期乳腺癌治疗进展

2019-10-27

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

病例:曲妥“方舟”，HER2阳性乳腺癌的“新”希望

2019-10-18

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

2019ESMO|细说HER2阳性晚期乳腺癌治疗那些事儿

2019-10-16

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

专家共议MDT背景下HER2阳性胃癌的诊疗实践与思考

2019-10-15

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

HER2阳性乳腺癌治愈不再遥远

2019-10-15

闆锋旦 (审核中...)

前往app查看评论内容

#HER2阳性#

2019 ESMO|未雨绸缪——HER2阳性乳腺癌，别等疾病复发转移

2019-10-10

科室
- - 订阅+
  - 更多科室
工具
服务